Asparaginase treatment in childhood acute lymphoblastic leukaemia
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial looks at how a medicine called asparaginase affects blood clotting in children treated for acute lymphoblastic leukaemia (a type of blood cancer). It may help doctors better manage bleeding or clot risks during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is diagnosed with acute lymphoblastic leukaemia (ALL), a type of blood cancer
- Child is between 1 and 17 years old at diagnosis
- Child's treatment follows the ALLTogether1 protocol (a standard treatment plan)
- Parents or guardians have signed a consent form to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This study looks at why some patients have allergic reactions to asparaginase, a chemotherapy drug used to treat acute lymphoblastic leukemia. By studying blood samples taken before the consolidation phase, researchers hope to find ways to predict and manage these reactions.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.